Abstract:Background: Glioblastoma (GBM) is the most malignant primary brain tumor with a median survival of 15 months despite aggressive multimodal treatment. There is an urgent need for novel drug discovery for GBM. CSPG4/NG2 transmembrane proteoglycan is a validated target, upregulated in 50% of GBM patient tumours, drives malignant progression and is independently prognostic for poor survival. We have recently identified a cancer specific 13 bp frameshift deletion in the CSPG4/NG2 gene (CSPG4/NG2del13), which leads to reduced protein expression and slowed cell growth in vitro and tumor take in vivo. The 3D structure of CSPG4/NG2 has not yet been solved, and unsuited for structure prediction by AlphaFold2 due to its size and PTMs. The structure of CSPG4/NG2 domain 1 (residues 411-547), containing the site of the 13 bp deletion, has been solved using cryo-EM and can be useful for new drug design. We hypothesize that a small-molecule inhibitor that binds to this 13 bp region of the CSPG4/NG2 proteoglycan, might induce the same phenotype as the 13 bp deletion. Methods: Using the published structure of domain 1, we performed in silico analysis to predict binding sites and docked 1280 compounds from the Prestwick Chemical library's database of FDA-approved drugs to these sites. The high ranked hits were further tested in vitro in GBM cells. Clonogenic survival, cell proliferation and scratch-wound assays were performed in patient derived P3, A172 and in CSPG4/NG2del13 heterozygous (HZ) GBM cells, that served as controls. Results: Three binding sites were found in the close proximity to the 13 bp deletion region within the N-terminal domain 1 of CSPG4/NG2. Docking analysis revealed multiple drug candidates bound to the predicted binding site, three of which were further analyzed. Dopamine is found to closely interact with CSPG4/NG2 domain 1, near the 13 bp deletion site, forming hydrogen bonds with Glu413 and Glu521. Pyrazinamide forms two hydrogen bonds with Glu521. 5-Azacytidine fits well into active site 1, establishing hydrogen bonds with key residues Gly475, Glu482, Val472 and Thr473. The in vitro functional assays showed that the top hits have a dose dependent negative effect on colony formation and cell proliferation in P3 and A172 GBM cells (P < 0.0001). The treatment with the same drug IC50 doses led to a growth rescue in the CSPG4/NG2del13 HZ cells compared to the WT cells (P < 0.001). 5-Azacytidine showed a significant inhibitory effect (P < 0.0001) on cell migration in P3, A172 GBM cells and also in HZ cells, (P < 0.001). Conclusion: The residues spanning the site of 13 bp deletion have chemical motifs that are salient for docking small molecule inhibitors that disrupt CSPG4/NG2 function. N-terminus domain 1 and full-length CSPG4/NG2 proteins for Cryo-EM 3D structure determination are being used to interrogate biochemical kinetics and identify new target regions. Citation Format: Lasse Neset, Mia Kristin Nilsen, Victoria Smith Arnesen, Kazi Asraful Alam, Martha Chekenya, Mohummad Aminur Rahman. Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4494.

Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells

STEM-20. RADIO-SENSITIZING GLIOBLASTOMA CANCER STEM CELLS BY INHIBITION OF FACT

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells

A covalent creatine kinase inhibitor ablates glioblastoma migration and sensitizes tumors to oxidative stress

Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.

Depletion of Glioma Stem Cells by Synergistic Inhibition of Mtor and C-Myc with a Biological Camouflaged Cascade Brain-Targeting Nanosystem.

Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors

Dddr-42. Leveraging Genome-Wide Crispr/Cas9 Knockout Drug Screens To Identify Sensitizers For Proteosome Inhibitors In Glioblastoma

Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells

Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway Against Glioblastoma.

Abstract 4494: Cryo-EM structure-based small molecule inhibitor drugs targeting CSPG4/NG2 in glioblastoma

STEM-22. TARGETING PYRIMIDINE SYNTHESIS ACCENTUATES MOLECULAR THERAPY RESPONSE IN GLIOBLASTOMA STEM CELLS

PRMT5 inhibition disrupts splicing and stemness in glioblastoma

STEM-14. GLIOBLASTOMA STEM CELL TARGETING CHIMERIC ANTIGEN RECEPTOR T CELLS MODIFIED USING PHAGE DISPLAY ISOLATED PEPTIDES

SUV39H1 Preserves Cancer Stem Cell Chromatin State and Properties in Glioblastoma

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

Targeted Nanotechnology in Glioblastoma Multiforme